REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Fidler IJ. Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2’-deoxyuridine. J Natl Cancer Inst 1970;45:773-82.
3. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 2014;158:1110-22.
4. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.
5. Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res 2008;14:2593-600.
6. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012;13:688-95.
7. Zhang L, Riethdorf S, Wu G, Wang T, Yang K, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 2012;18:5701-10.
8. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA 2006;296:193-201.
9. Kawai M, Minami Y, Kuriyama S, Kakizaki M, Kakugawa Y, et al. Adiposity, adult weight change and breast cancer risk in postmenopausal Japanese women: the Miyagi Cohort Study. Br J Cancer 2010;103:1443-7.
10. Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, et al. Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 2004;111:762-71.
11. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006;6:130-40.
12. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009;8:909-15.
13. Baneres Amella J, Alonso Caballero J, Anto Boque JM. The appropriateness of hospital admissions. Med Clin (Barc) 1990;95:357-8.
14. Mu L, Zhu N, Zhang J, Xing F, Li D, et al. Type 2 diabetes, insulin treatment and prognosis of breast cancer. Diabetes Metab Res Rev 2017;33.
15. Mego M, Giordano A, De Giorgi U, Masuda H, Hsu L, et al. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast Cancer Res 2015;17:2.
16. Brewer TM, Masuda H, Liu DD, Shen Y, Liu P, et al. Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer 2013;109:318-24.
17. Mego M, Karaba M, Minarik G, Benca J, Silvia J, et al. Circulating tumor cells with epithelial-to-mesenchymal transition phenotypes associated with inferior outcomes in primary breast cancer. Anticancer Res 2019;39:1829-37.
18. Cierna Z, Mego M, Janega P, Karaba M, Minarik G, et al. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer. BMC Cancer 2014;14:472.
19. Mego M, Karaba M, Minarik G, Benca J, Sedlackova T, et al. Relationship between circulating tumor cells, blood coagulation, and urokinase-plasminogen-activator system in early breast cancer patients. Breast J 2015;21:155-60.
20. Mego M, Cholujova D, Minarik G, Sedlackova T, Gronesova P, et al. CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer. BMC Cancer 2016;16:127.
21. Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 2011;29:40-6.
22. Wairagu PM, Phan AN, Kim MK, Han J, Kim HW, et al. Insulin priming effect on estradiol-induced breast cancer metabolism and growth. Cancer Biol Ther 2015;16:484-92.
23. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009;101:48-60.
24. Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 2010;16:1695-700.
25. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27:3297-302.
26. Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, et al. Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes. J Cancer 2013;4:549-56.
27. Sorensen GV, Ganz PA, Cole SW, Pedersen LA, Sorensen HT, et al. Use of beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. J Clin Oncol 2013;31:2265-72.
28. Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat 2011;129:549-56.
29. Holmes MD, Hankinson SE, Feskanich D, Chen WY. Beta blockers and angiotensin-converting enzyme inhibitors’ purported benefit on breast cancer survival may be explained by aspirin use. Breast Cancer Res Treat 2013;139:507-13.
